These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6265140)

  • 1. Metabolism of antithrombin III in cirrhosis and carcinoma of the liver.
    Chan V; Lai CL; Chan TK
    Clin Sci (Lond); 1981 Jun; 60(6):681-8. PubMed ID: 6265140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of fibrinogen in cirrhosis of the liver.
    Tytgat GN; Collen D; Verstraete M
    J Clin Invest; 1971 Aug; 50(8):1690-701. PubMed ID: 5163179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombin III transfusion in patients with hepatic cirrhosis.
    Schipper HG; ten Cate JW
    Br J Haematol; 1982 Sep; 52(1):25-33. PubMed ID: 7115627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombin III metabolism in patients with liver disease.
    Knot E; Ten Cate JW; Drijfhout HR; Kahlé LH; Tytgat GN
    J Clin Pathol; 1984 May; 37(5):523-30. PubMed ID: 6725600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catabolism and distribution of functionally heterogeneous human antithrombin III.
    Marciniak E; Romond EH
    J Lab Clin Med; 1987 Jan; 109(1):89-96. PubMed ID: 3794520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration.
    Collen D; Schetz J; de Cock F; Holmer E; Verstraete M
    Eur J Clin Invest; 1977 Feb; 7(1):27-35. PubMed ID: 65284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group.
    Schwartz RS; Bauer KA; Rosenberg RD; Kavanaugh EJ; Davies DC; Bogdanoff DA
    Am J Med; 1989 Sep; 87(3B):53S-60S. PubMed ID: 2679072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some immunological investigations on antithrombin III 'Budapest'.
    Lane JL
    Br J Haematol; 1978 Nov; 40(3):459-70. PubMed ID: 107959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transfusion studies in patients with familial antithrombin III (ATIII) deficiency: half-disappearance time of infused ATIII and influence of such infusion on platelet life-span.
    Winter JH; Fenech A; Bennett B; Douglas AS
    Br J Haematol; 1981 Nov; 49(3):449-53. PubMed ID: 7295588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of antithrombin III levels for outcomes in patients with hepatocellular carcinoma after curative hepatectomy.
    Iwako H; Tashiro H; Amano H; Tanimoto Y; Oshita A; Kobayashi T; Kuroda S; Tazawa H; Nambu J; Mikuriya Y; Abe T; Ohdan H
    Ann Surg Oncol; 2012 Sep; 19(9):2888-96. PubMed ID: 22466667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered levels of antithrombin III and fibrinogen in the aortic wall of the alloxan-induced diabetic rabbit: evidence of a prothrombotic state.
    Witmer MR; Hadcock SJ; Peltier SL; Winocour PD; Richardson M; Hatton MW
    J Lab Clin Med; 1992 Mar; 119(3):221-30. PubMed ID: 1541872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antithrombin III concentrate use in patients with cirrhosis with coagulation disorders].
    Ribeiro AA; Lourenço DM; Toledo CF; Noguti MA; Borges DR
    Rev Assoc Med Bras (1992); 1997; 43(3):189-94. PubMed ID: 9497544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early prediction of postoperative liver dysfunction and clinical outcome using antithrombin III-activity.
    Pereyra D; Offensperger F; Klinglmueller F; Haegele S; Oehlberger L; Gruenberger T; Brostjan C; Starlinger P
    PLoS One; 2017; 12(4):e0175359. PubMed ID: 28406940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombin III-beta associates more readily than antithrombin III-alpha with uninjured and de-endothelialized aortic wall in vitro and in vivo.
    Witmer MR; Hatton MW
    Arterioscler Thromb; 1991; 11(3):530-9. PubMed ID: 2029494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing risk stratification in portal vein thrombosis after splenectomy and its primary prophylaxis with antithrombin III concentrates and danaparoid sodium in liver cirrhosis with portal hypertension.
    Kawanaka H; Akahoshi T; Itoh S; Iguchi T; Harimoto N; Uchiyama H; Yoshizumi T; Shirabe K; Takenaka K; Maehara Y
    J Am Coll Surg; 2014 Nov; 219(5):865-74. PubMed ID: 25256370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate.
    Büller HR; ten Cate JW
    Am J Med; 1989 Sep; 87(3B):44S-48S. PubMed ID: 2679070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic index of liver cirrhosis with ascites with and without hepatocellular carcinoma.
    Yoneyama K; Taniguchi H; Kiuchi Y; Shibata M; Mitamura K
    Scand J Gastroenterol; 2004 Dec; 39(12):1272-9. PubMed ID: 15743006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor IX concentrate therapy and thrombosis: relation to changes in plasma antithrombin III.
    Hoffman C; Hultin MB
    Thromb Res; 1986 Jul; 43(2):143-51. PubMed ID: 3738857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative catabolism of prothrombin and antithrombin in normal and alloxan-diabetic rabbits.
    Hatton MW; Southward SM; Blajchman MA; Ross B; Winocour PD; Richardson M
    Metabolism; 1997 Dec; 46(12):1406-11. PubMed ID: 9439534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of recombinant human soluble thrombomodulin (rhs-TM) on a rat model of disseminated intravascular coagulation with decreased levels of plasma antithrombin III.
    Aoki Y; Ohishi R; Takei R; Matsuzaki O; Mohri M; Saitoh K; Gomi K; Sugihara T; Kiyota T; Yamamoto S
    Thromb Haemost; 1994 Apr; 71(4):452-5. PubMed ID: 8052962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.